Literature DB >> 23624850

Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling.

Kwan-Young Jung1, Ramin Samadani, Jay Chauhan, Kerrick Nevels, Jeremy L Yap, Jun Zhang, Shilpa Worlikar, Maryanna E Lanning, Lijia Chen, Mary Ensey, Sagar Shukla, Rosene Salmo, Geoffrey Heinzl, Caryn Gordon, Troy Dukes, Alexander D MacKerell, Paul Shapiro, Steven Fletcher.   

Abstract

We herein report on the pharmacophore determination of the ERK docking domain inhibitor (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione, which has led to the discovery of compounds with greater selectivities for inhibiting the proliferation of melanoma cells containing active ERK signaling.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23624850      PMCID： PMC3663054          DOI： 10.1039/c3ob40199e

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN： 1477-0520            Impact factor:   3.876


  47 in total

1.  Discovery of 3-(2-aminoethyl)-5-(3-phenyl-propylidene)-thiazolidine-2,4-dione as a dual inhibitor of the Raf/MEK/ERK and the PI3K/Akt signaling pathways.

Authors:  Qianbin Li; Jingde Wu; Hui Zheng; Kai Liu; Tai L Guo; Yuying Liu; Scott T Eblen; Steven Grant; Shijun Zhang
Journal:  Bioorg Med Chem Lett       Date:  2010-06-08       Impact factor: 2.823

2.  Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.

Authors:  Y N Vashisht Gopal; Wanleng Deng; Scott E Woodman; Kakajan Komurov; Prahlad Ram; Paul D Smith; Michael A Davies
Journal:  Cancer Res       Date:  2010-10-19       Impact factor: 12.701

3.  High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886).

Authors:  Jieru Meng; Henry Peng; Bingbing Dai; Wei Guo; Li Wang; Lin Ji; John D Minna; Christine M Chresta; Paul D Smith; Bingliang Fang; Jack A Roth
Journal:  Cancer Biol Ther       Date:  2009-11-18       Impact factor: 4.742

Review 4.  Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists.

Authors:  Brent N Rexer; Jeffrey A Engelman; Carlos L Arteaga
Journal:  Cell Cycle       Date:  2009-01-30       Impact factor: 4.534

Review 5.  Development of extracellular signal-regulated kinase inhibitors.

Authors:  Kimberly Burkhard; Sarice Smith; Rahul Deshmukh; Alexander D MacKerell; Paul Shapiro
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

6.  Peroxisome proliferator-activating receptors: a new way to treat melanoma?

Authors:  Dirk Schadendorf
Journal:  J Invest Dermatol       Date:  2009-05       Impact factor: 8.551

7.  Structure-activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: development of potential substrate-specific ERK1/2 inhibitors.

Authors:  Qianbin Li; Adnan Al-Ayoubi; Tailiang Guo; Hui Zheng; Aurijit Sarkar; Tri Nguyen; Scott T Eblen; Steven Grant; Glen E Kellogg; Shijun Zhang
Journal:  Bioorg Med Chem Lett       Date:  2009-09-18       Impact factor: 2.823

8.  RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Authors:  Poulikos I Poulikakos; Chao Zhang; Gideon Bollag; Kevan M Shokat; Neal Rosen
Journal:  Nature       Date:  2010-03-18       Impact factor: 49.962

9.  ABA inhibits germination but not dormancy release in mature imbibed seeds of Lolium rigidum Gaud.

Authors:  Danica E Goggin; Kathryn J Steadman; R J Neil Emery; Scott C Farrow; Roberto L Benech-Arnold; Stephen B Powles
Journal:  J Exp Bot       Date:  2009-06-01       Impact factor: 6.992

10.  Cell fate decisions are specified by the dynamic ERK interactome.

Authors:  Daniela Baiocchi; Marc Birtwistle; Alex von Kriegsheim; David Sumpton; Willy Bienvenut; Nicholas Morrice; Kayo Yamada; Angus Lamond; Gabriella Kalna; Richard Orton; David Gilbert; Walter Kolch
Journal:  Nat Cell Biol       Date:  2009-11-22       Impact factor: 28.824
View more
  5 in total

1.  Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf.

Authors:  Ramin Samadani; Jun Zhang; Amanda Brophy; Taiji Oashi; U Deva Priyakumar; E Prabhu Raman; Franz J St John; Kwan-Young Jung; Steven Fletcher; Edwin Pozharski; Alexander D MacKerell; Paul Shapiro
Journal:  Biochem J       Date:  2015-05-01       Impact factor: 3.857

2.  A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases.

Authors:  Chad J Miller; Yagmur Muftuoglu; Benjamin E Turk
Journal:  Biochem Pharmacol       Date:  2017-06-21       Impact factor: 5.858

3.  Structure-based design, synthesis, and biological evaluation of novel pyrimidinone derivatives as PDE9 inhibitors.

Authors:  Xu-Nian Wu; Ya-Dan Huang; Jin-Xuan Li; Yan-Fa Yu; Zhou Qian; Chen Zhang; Yinuo Wu; Hai-Bin Luo
Journal:  Acta Pharm Sin B       Date:  2018-03-12       Impact factor: 11.413

Review 4.  5-Ene-4-thiazolidinones - An efficient tool in medicinal chemistry.

Authors:  Danylo Kaminskyy; Anna Kryshchyshyn; Roman Lesyk
Journal:  Eur J Med Chem       Date:  2017-09-20       Impact factor: 6.514

5.  Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo.

Authors:  Tamer S Kaoud; William H Johnson; Nancy D Ebelt; Andrea Piserchio; Diana Zamora-Olivares; Sabrina X Van Ravenstein; Jacey R Pridgen; Ramakrishna Edupuganti; Rachel Sammons; Micael Cano; Mangalika Warthaka; Matthew Harger; Clint D J Tavares; Jihyun Park; Mohamed F Radwan; Pengyu Ren; Eric V Anslyn; Kenneth Y Tsai; Ranajeet Ghose; Kevin N Dalby
Journal:  Nat Commun       Date:  2019-11-19       Impact factor: 14.919
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.